Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
44 studies found for:    Small Cell Cancer of the Bladder | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Condition: Bladder Cancer
Interventions: Radiation: Prophylactic Cranial Irradiation (PCI);   Other: Brain X-ray
2 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Breast Cancer;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Bladder Cancer
Intervention: Drug: IMMU-132
3 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult Pineal Gland Astrocytoma;   Adult Solid Neoplasm;   AIDS Related Immunoblastic Lymphoma;   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Diffuse Mixed Cell Lymphoma;   AIDS-Related Diffuse Small Cleaved Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   AIDS-Related Lymphoblastic Lymphoma;   AIDS-Related Lymphoma;   AIDS-Related Primary Central Nervous System Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Carcinoma;   Extra-Adrenal Paraganglioma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Gastrin-Producing Neuroendocrine Tumor;   Hepatic Complication;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lung Carcinoid Tumor;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Male Breast Carcinoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Nasal Cavity Inverted Papilloma;   Nodal Marginal Zone Lymphoma;   Olfactory Neuroblastoma;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Inverted Schneiderian Papilloma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Lip Basal Cell Carcinoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Merkel Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasal Type NK/T-Cell Lymphoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Olfactory Neuroblastoma;   Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Oral Cavity Mucoepidermoid Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Oropharyngeal Undifferentiated Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Adrenal Gland Pheochromocytoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Small Intestinal Lymphoma;   Somatostatin-Producing Neuroendocrine Tumor;   Splenic Marginal Zone Lymphoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage III Adult Soft Tissue Sarcoma;   Stage III Bladder Cancer;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Laryngeal Verrucous Carcinoma;   Stage III Lip and Oral Cavity Squamous Cell Carcinoma;   Stage III Lip Basal Cell Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Merkel Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Nasal Type NK/T-Cell Lymphoma;   Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage III Oral Cavity Adenoid Cystic Carcinoma;   Stage III Oral Cavity Mucoepidermoid Carcinoma;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage III Oropharyngeal Undifferentiated Carcinoma;   Stage III Pancreatic Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IV Nasal Type NK/T-Cell Lymphoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Basal Cell Lip Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVA Oral Cavity Mucoepidermoid Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Undifferentiated Carcinoma;   Stage IVA Rectal Cancer;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Basal Cell Lip Carcinoma;   Stage IVB Colon Cancer;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Oral Cavity Mucoepidermoid Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Undifferentiated Carcinoma;   Stage IVB Rectal Cancer;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Basal Cell Lip Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Oral Cavity Mucoepidermoid Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Undifferentiated Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Tongue Carcinoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Romidepsin;   Other: Pharmacological Study
4 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Not yet recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
6 Unknown  Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
Condition: Bladder Cancer
Interventions: Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: sorafenib tosylate;   Other: imaging biomarker analysis;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Procedure: neoadjuvant therapy;   Radiation: fludeoxyglucose F 18
7 Recruiting Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Solid Tumors
Interventions: Drug: STM 434;   Drug: Liposomal doxorubicin
8 Recruiting A Phase 1/2 Study to Evaluate MEDI4736
Condition: Advanced Solid Tumors
Intervention: Drug: MEDI4736
9 Recruiting A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
10 Recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
11 Recruiting Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Conditions: Transitional Cell Carcinoma;   Bladder Cancer;   Carcinoma in Situ;   Carcinoma in Situ Concurrent With Papillary Tumors
Interventions: Biological: CG0070 adenovirus vector;   Other: Control Arm: Quadruple Choice
12 Not yet recruiting Alisertib in Chemotherapy-pretreated Urothelial Cancer
Conditions: Bladder Cancer;   Transitional Cell Carcinoma
Interventions: Drug: Alisertib;   Drug: Paclitaxel;   Drug: Placebo
13 Recruiting Improving Sensitivity of Urine Cytology for Bladder Cancer
Condition: Bladder Cancer
Intervention: Device: La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration
14 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Urothelial Carcinoma;   Distal Urethral Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Proximal Urethral Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Urethra Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Stage IV Urethral Cancer;   Ureter Carcinoma
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Other: Placebo;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis
15 Unknown  External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Condition: Cancer
Interventions: Drug: indinavir sulfate;   Drug: ritonavir;   Radiation: radiation therapy
16 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
17 Recruiting Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Conditions: Prostate Cancer;   Bladder Cancer;   Kidney Cancer
Intervention: Drug: Ferumoxytol
18 Unknown  Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Other: questionnaire administration;   Procedure: quality-of-life assessment;   Procedure: robot-assisted laparoscopic surgery;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery
19 Not yet recruiting TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Glioma/Medulloblastoma;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
20 Recruiting Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Conditions: Adenocarcinoma of the Bladder;   Recurrent Bladder Cancer;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Drug: sirolimus;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years